Idera of­fi­cial­ly puts to rest its Phase III tri­al in ad­vanced melanoma; BeiGene nabs pri­or­i­ty re­view for sN­DA

Idera dropped some dis­ap­point­ing news in late March, when it showed its lead drug failed to hit its pri­ma­ry end­point in a Phase III tri­al. Now, Idera, which worked with Bris­tol My­ers Squibb to test the drug, known as tilso­tolimod, in com­bi­na­tion with ip­il­i­mum­ab ver­sus ip­il­i­mum­ab alone in pa­tients with an­ti-PD-1 re­frac­to­ry ad­vanced melanoma, is say­ing that tri­al will not fin­ish.

“Our con­clu­sion is that the to­tal­i­ty of the da­ta, with all pa­tients hav­ing com­plet­ed the study treat­ment, does not sup­port the like­li­hood that the com­bi­na­tion of tilso­tolimod with ip­il­i­mum­ab would achieve a sta­tis­ti­cal­ly sig­nif­i­cant OS ben­e­fit over ip­il­i­mum­ab alone,” Vin­cent Mi­lano, Idera’s CEO, said in a state­ment on Wednes­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER